 Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 azilsartan medoxomil is an angiotensin II receptor blocker being evaluated by Takeda to treat essential hypertension. 